Benchling

It's been used by more than 2 million researchers. It's been cited in 30,000 scientific papers. It's only been 4 years since its debut, and already its impact on science goes far and wide. You guessed it — it's #AlphaFold. #AI is having a huge moment this week. Just think: It took 8 years before the Nobel Prize was awarded for CRISPR. That this technology was recognized so quickly is a mark of how transformative it could be. “We think there’s huge potential there to revolutionize, actually, the way drug discovery is done and try to shorten it down from almost a decade or more of work, usually, to get a drug all the way through out into the world, to instead of years, maybe months," said Nobel Prize winner Demis Hassabis. https://lnkd.in/eWWsv6mB

This year, we’re delighted to welcome John Tsai, MD for a fireside chat at #Benchtalk London! As the CEO of Forcefield Therapeutics, executive partner at Syncona Limited and former CMO at Novartis, John is known for pushing the boundaries of science to develop life-saving treatments. He’ll share his perspective on hot topics like bringing cell and gene therapies to market, building a biotech in Europe during unstable times, and the growing role of software and tech in R&D. Join us on 23 October — there’s still time to register! https://lnkd.in/gRyw8q2v

Global leader Novonesis is building the foundation for a new era of smarter, faster, and more connected R&D — with Benchling as their digital R&D platform. After merging Novozymes and Chr. Hansen to create Novonesis, a unified data model was critical for integrating their teams and driving collaboration across 1,500 scientists. We are proud to support Novonesis, as they reach over 4 billion people daily with biosolutions that increase fuel efficiency, improve crop resilience, and more. https://lnkd.in/eaHMeDA3 #BuiltOnBenchling

6 years ago, when we held our first #Benchtalk at a small bar in Cambridge, we were happy to have even a handful of customers join us. Now, Benchtalk is a huge community event, with almost 500 scientists, data scientists, and tech leaders gathering to learn from each other. A lot has changed since Benchling started. We’ve seen dramatic changes in biotech: the rise of CRISPR, the shift to biologics, and now — rapid growth in computational science. But today’s biotechs are still spending too much time solving foundational problems before they can even get to their novel AI/ML applications. Things like getting their wet lab data “computation-ready” to train models, or rebuilding routine analysis pipelines. That’s why we’re investing in powering the dry lab. At #Benchtalk, we shared a preview of what’s next: 1. Biomolecule representation: Reducing work for dry labs with science aware data models for complex biomolecules. This year, we delivered support for oligo conjugates — deeper support for complex antibody formats, including multi-specifics and antibody-drug conjugates, is next. 2. Experimental data access: Simplifying how dry labs access wet lab data for model development, including using LLMs to automate writing queries. 3. Computational analysis: Helping dry labs offload standardized work with OOB solutions for complex data analysis. Science is moving faster than ever before, and now, so is technology. I truly believe that connecting the dry and wet labs is how we accelerate computational science and ultimately, get to breakthroughs faster. I can’t wait to see where this next year will take us.

🤔 Did you know? As of 2023, women held 10.6% of CEO positions in Fortune 500 companies, and around 30% of board seats. How do we change that? This year at #Benchtalk London, we're reflecting on ways to challenge bias, advocate for equitable opportunities, and create inclusive environments. Join us for our #WomenInBiotech panel, featuring powerhouse women and men driving change in #biotech: Dr Uzma Choudry, Kathryn Golden, Jason Mellad, Richard Hopkins, Karen Ambrose, and Meritxell Orpinell, PhD, PMP. Join us in London 🇬🇧 on 23-24 October. Register now: https://lnkd.in/gRyw8q2v

Thank you to the nearly 500 scientific, ML, and digital leaders that made Benchtalk Boston a huge success. I returned home full of optimism for scientific progress and energized to build new tools for you. This Benchtalk felt different because biology and compute really have converged. New Bio AI tools are generating more high quality molecule ideas and LLMs thoughtfully applied are going to reduce toil at every step of R&D. Software might actually catch science! We shared major investments in three areas to make this happen: 1. Scaling wet lab throughput massively: Automated, end-to-end workflows that connect experimental design, instrument data capture, and data analysis for wet lab scientists. 2. Building the pipes to connect wet and dry labs: Molecule aware data models to reduce data prep and built-in scientific analytics to offload basic dry lab workflows, enabling computational scientists to focus on truly novel ML. 3. Open platform to connect the ecosystem: Reusable integrations and shareable apps for third-party systems ranging from reference databases, to equipment management, and data lakes. I would also like to extend my thanks to Mathai Mammen, M.D., Ph.D., for an inspiring fireside chat. He shared his journey, from founding Theravance out of grad school to leading R&D at J&J, and offered valuable insights on decision-making to maximize human impact. It was a powerful reminder on the importance of having a personal mission and staying curious.

“A lot of the traditional challenges that existed for AI/ML usage are still there today — and to some degree, are even higher priority,” says Benchling CTO Stephen Deasy. Sometimes it’s fundamental issues like data access, data quality, and whether the data are structured for your AI models. But this is where cloud technology can help. Listen to #TechTalksDaily to hear what Stephen has to say about how #AI is revolutionizing R&D, and how to successfully integrate AI into your research. https://lnkd.in/egjbuUcn Tech Blog Writer

Digitalizing and accelerating the pace of biotech research with #Astrix and Benchling. Excited to be a part of #Benchtalk 2024 in Boston, MA

This week, I joined the Benchling's global community of R&D scientists and technology leaders at Benchtalk 2024. I had the opportunity to attend the community-led sessions on the latest trends in biotech, get hands-on Benchling training and best practices from product experts, and network with 300+ industry peers. Thank you, Eli Lilly and Company for this opportunity!

I just wrapped up two incredible days at #BenchTalk in Boston! 🎉 Highlights include: ✌️Meeting some of our awesome US based clients in person for the first time 🎁 New Benchling product releases (Including powerful integrated ML features) 🪼 Finally meeting the world famous JeffyP in person I'm very much looking forward to the London BenchTalk in a couple of weeks! 🚀